TRD2 - Ultrahigh Field Molecular Imaging and Spectroscopy

TRD2 - 超高场分子成像和光谱

• 批准号: 10549854
• 负责人: Gregory John Metzger
• 金额: $ 31.63万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-02-01 至 2024-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10549854
• 关键词: Acceleration; Address; Aging; Alzheimer' s Disease; Automobile Driving; Biological Markers; Biological Process; Cell Nucleus; Cell physiology; Chemical Shift Imaging; Communities; Data; Degenerative polyarthritis; Deposition; Detection; Development; Diffusion; Disease; Electrolytes; Electromagnetic Fields; Freedom; Frequencies; Functional disorder; Funding; Goals; Heating; Human; Human body; Image; Ions; Link; Magnetic Resonance; Magnetic Resonance Imaging; Malignant Neoplasms; Maps; Measures; Metabolic; Methods; Modeling; Molecular; Molecular Probes; Monitor; Multiple Sclerosis; Musculoskeletal Diseases; Myelin; Neurodegenerative Disorders; Noise; Nuclear; Pathology; Physiologic pulse; Preparation; Process; Property; Protons; Relaxation; Research; Resolution; Resources; Rotation; Running; Scanning; Sensitivity and Specificity; Signal Transduction; Sodium; Spatial Distribution; Spectrum Analysis; Speed; System; Technology; Time; Tissue Viability; Tissues; United States National Institutes of Health; Visualization; absorption; body system; connectome; design; disease diagnosis; driving force; experience; flexibility; imaging approach; imaging modality; imaging platform; imaging study; improved; in vivo; innovation; insight; interest; magnetic field; molecular dynamics; molecular imaging; molecular marker; next generation; novel; parametric imaging; predictive tools; radio frequency; reconstruction; spectroscopic imaging; transmission process; treatment response

SUMMARY / ABSTRACT The main goal of this project is to develop an ultrahigh field (UHF) magnetic resonance imaging (MRI) platform for molecular imaging as an increasingly sensitive molecular imaging platform to visualize, characterize, and measure biological processes at the molecular and cellular levels. We will realize the advantages of increases signal-to-noise ratio and spectral dispersion afforded by increased static magnetic fields while overcoming its multiple challenges through the development of novel system solutions, acquisition methods and reconstruction strategies. This platform will be developed on a unique 10.5T whole body MRI scanner and will make use of advanced radiofrequency (RF) management afforded by a 16 channel parallel transmit (pTx) system. Three specific molecular imaging strategies we will pursued in this project, each detailed in a specific aim. In SA1, we will develop a platform for integrated and advanced multinuclear applications at UHF where the proton (1H) channel can transmit more efficiently using pTx and the single x-nuclei channel (i.e. 31P, 23Na, or 13C) can either be used within the same session or the same scan, the later enabling advanced multinuclear applications. This functionality currently does not exist on current systems and is mandatory for 10.5T. In SA2, we will use pTx RF pulse design methods to create novel accelerated spatial-spectral pulses for improved spectroscopic imaging studies with reduced transmit field sensitivity, B0 sensitivity and echo times. Model-based reconstruction strategies will then allow us accelerate the acquisitions while providing improved estimates of metabolite and compartment specific, parameters such as T2 and/or diffusion which are correlated with both aging and disease. In SA3, we will use dynamic RF shimming and RF pulse design strategies to improve the magnetization preparation for rotating frame relaxation methods used to probe molecular dynamics. Readout and reconstruction strategies will also be explored to improve SNR efficiency and to accelerate relaxation rate mapping. Finally in both SA1 and SA3 we will explore the use and optimization of ultrashort echo time imaging methods to capture signals from short T2 spins as when imaging sodium or when trying to measure the relaxation rate properties of myelin. In total, the development of this molecular imaging platform will provide unparalleled functionality and sensitivity to probe molecular parameters to characterize tissue through molecular dynamics, spatial distributions of functional metabolic parameters and advanced multinuclear studies. The developed technologies will enhance the driving collaborative projects which focus on exploring new biomarkers to diagnose disease, monitor progression and evaluate treatment response in a variety of pathologies including osteoarthritis, multiple sclerosis, Alzheimer's and cancer. While the main focus is on the implementation of these methods at 10.5T for the highest sensitivity gains, the methods can positively impact 7T systems and in some cases even lower fields.

摘要/摘要 该项目的主要目标是开发超高场（UHF）磁共振成像（MRI）平台 用于分子成像作为日益敏感的分子成像平台，用于可视化、表征和 在分子和细胞水平上测量生物过程。我们将意识到增加的优势 增加静磁场提供的信噪比和频谱色散，同时克服其 通过开发新颖的系统解决方案、采集方法和重建来应对多重挑战 策略。该平台将在独特的 10.5T 全身 MRI 扫描仪上开发，并将利用 16 通道并行传输 (pTx) 系统提供先进的射频 (RF) 管理。三 我们将在这个项目中采用特定的分子成像策略，每个策略都有一个特定的目标。在 SA1 中，我们 将开发一个用于超高频集成和先进多核应用的平台，其中质子（1H） 通道可以使用 pTx 更有效地传输，并且单 x 核通道（即 31P、23Na 或 13C）可以 可在同一会话或同一扫描中使用，后者可启用高级多核应用程序。这 当前系统上不存在该功能，并且对于 10.5T 是强制的。在 SA2 中，我们将使用 pTx RF 脉冲设计方法创建新颖的加速空间光谱脉冲以改进光谱成像 降低发射场灵敏度、B0 灵敏度和回波时间的研究。基于模型的重建 然后，战略将使我们能够加速收购，同时提供改进的代谢物和 与衰老和疾病相关的隔室特异性参数，例如 T2 和/或扩散。 在SA3中，我们将使用动态射频匀场和射频脉冲设计策略来提高磁化强度 用于探测分子动力学的旋转框架弛豫方法的准备。读数和 还将探索重建策略以提高信噪比效率并加速弛豫率 映射。最后在SA1和SA3中我们将探讨超短回波时间成像的使用和优化 在钠成像或尝试测量弛豫时捕获短 T2 自旋信号的方法 髓磷脂的速率特性。总的来说，该分子成像平台的开发将提供无与伦比的 探测分子参数以通过分子动力学表征组织的功能和灵敏度， 功能代谢参数的空间分布和高级多核研究。所开发的 技术将增强推动合作项目，重点是探索新的生物标志物来诊断 疾病，监测进展并评估各种病理的治疗反应，包括骨关节炎， 多发性硬化症、阿尔茨海默氏症和癌症。虽然主要重点是这些方法的实施 10.5T 以获得最高灵敏度增益，这些方法可以对 7T 系统产生积极影响，在某些情况下甚至 较低的字段。